| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 0.25 Billion |
| Market Size (2030) | USD 1.05 Billion |
| CAGR (2025 - 2030) | 33.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Microbiome Therapeutics Market Analysis
The Microbiome Therapeutics Market size is estimated at USD 0.25 billion in 2025, and is expected to reach USD 1.05 billion by 2030, at a CAGR of 33.6% during the forecast period (2025-2030).
Key drivers of the market include heightened research activities aimed at developing microbiome therapeutics, a surge in the prevalence of targeted diseases like Clostridium difficile infection, diabetes, and Crohn’s disease, and strategies such as product launches by industry leaders.
Intensified research into novel microbiome therapeutics is poised to enhance the availability of treatments for Clostridium difficile and Crohn's disease, thereby propelling the market during the forecast period.
For example, in January 2022, BiomeBank, a clinical-stage company specializing in microbiome therapeutics, forged a 4-year collaboration with Hudson Institute. This partnership bolsters Hudson Institute’s vision for Australia's inaugural National Centre for Inflammation Research (NCIR). The collaboration will primarily target developing specific microbial therapies to address unmet medical needs in patients with Inflammatory Bowel Disease (IBD). Such collaborations are pivotal in accelerating research and development in the microbiome therapeutics arena.
Moreover, rising investments in startups focused on microbiome therapeutics are set to further energize the market. For instance, in February 2022, Biomica, an AI-Driven provider of Microbiome-Based Therapeutics, secured a USD 20 million investment from Shanghai Healthcare Capital (SHC). Biomica intends to channel this funding into advancing its microbiome-based therapeutic pipeline. Such financial backing not only expedites the introduction of innovative microbiome therapeutics but also broadens their market accessibility.
Additionally, product launches by industry leaders are anticipated to bolster the accessibility and affordability of microbiome therapeutics. For instance, in April 2023, Seres Therapeutics, Inc., a key player in microbiome therapeutics, reported that the United States Food and Drug Administration greenlit its product, Vowst. This oral-fecal microbiota product is designed to prevent the recurrence of Clostridioides difficile (C. difficile) infection in adults post-antibacterial treatment. Such product introductions are crucial in enhancing the reach of microbiome therapeutics in the market.
In summary, bolstered research activities, increased investments, and strategic product launches are set to propel the market. Yet, the shadow of stringent regulatory guidelines looms, posing potential restraints.
Microbiome Therapeutics Market Trends
Clostridium Difficile(C.diff) Segment is Expected to Hold Significant Market Share Over the Forecast Period.
Clostridium difficile, a gram-positive, spore-forming bacterium, is an obligate anaerobic bacillus known for producing toxins that lead to diarrhea, commonly linked to antibiotic use. Due to its transmissibility and the morbidity and mortality it causes, this bacterium poses a significant public health challenge. The segment's growth is primarily driven by the rising prevalence of Clostridium difficile infections and strategic activities, notably new product launches by key industry players.
The increasing prevalence of Clostridium difficile infections (CDI) is anticipated to boost the demand for microbiome therapeutics, aiding in effective management and potentially lowering healthcare costs associated with hospital-acquired infections. This trend is expected to propel the market during the forecast period.
For instance, a March 2023 article in BMC Infectious Disease highlighted that Clostridioides difficile infections (CDI) impact around 500,000 individuals annually in the United States (U.S.). CDI poses significant clinical, social, and economic burdens. It's the primary cause of antibiotic- and healthcare-associated infective diarrhea in the U.S. The article also noted a surge in community-associated CDI, nearly doubling over the last decade, reaching an incidence of 63.3 cases per 100,000 individuals in 2022. Such a pronounced prevalence of CDI underscores the growing demand for innovative treatments like microbiome therapeutics, bolstering the market's growth during the forecast period.
Moreover, heightened strategic activities, including acquisitions, investments, and product approvals, are set to enhance the accessibility of microbiome therapeutics. This surge in accessibility is likely to amplify the demand for these treatments in managing CDI, further accelerating the market segment's growth.
For instance, in November 2022, Ferring, a specialty biopharmaceutical firm, announced that the U.S. Food and Drug Administration approved its product, Rebyota. This fecal microbiota therapeutic is designed to prevent the recurrence of Clostridioides difficile infection (CDI) in adults aged 18 and older, post-antibiotic treatment for recurrent CDI. The Bayesian model estimated an 8-week treatment success rate of 70.6% for Rebyota, compared to 57.5% for the placebo, boasting a 99.1% probability of Rebyota's superiority in curbing CDI recurrence after standard antibiotic treatment. Notably, over 90% of participants who responded to the treatment remained free from CDI recurrence for six months. Such product launches are poised to significantly influence the market's trajectory in the coming years.
In conclusion, the pronounced prevalence of Clostridioides difficile infections (CDI), coupled with strategic activities like the introduction of innovative microbiome therapeutics, is set to enhance the accessibility and affordability of these treatments, driving segment revenue in the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold the Significant Market Share Over the Forecast Period
In North America, the microbiome therapeutics market is propelled by several factors. These include the rising prevalence of chronic diseases like diabetes and Crohn’s Disease, a robust healthcare infrastructure, technological advancements, and strategic activities such as acquisitions and product launches.
The surge in chronic diseases, including diabetes, obesity, and Crohn’s, is spurring research into microbiome therapeutics for better disease management. For instance, data from the Centers for Disease Control and Prevention (CDC) in December 2022 highlighted that approximately 35% of United States (U.S.) adults were obese in 2022. States like Louisiana, Oklahoma, and West Virginia reported obesity rates nearing 40%. Similarly, a November 2023 report from the Canadian Community Health Survey noted about 8 million Canadians grapple with obesity, with projections suggesting that 30% of Canadians aged 18 and older would be affected in 2022. Such rising chronic disease prevalence, especially obesity, is set to boost research into innovative microbiome therapeutics, propelling the market forward.
Moreover, technological strides in developing microbiome therapeutics are likely to bolster their adoption for various ailments, further fueling market growth. For instance, a May 2024 article in the American Gastroenterological Association Journal highlighted advancements in next-generation sequencing and functional assessment of human microbiota. These breakthroughs have significantly enhanced the study and manipulation of the gastrointestinal microbiome, aiding in the treatment of gastrointestinal, hepatic, and extraintestinal conditions. Thus, the integration of genomics in crafting precision microbiome therapeutics is poised to usher in a wave of new product launches in North America, driving the market.
Additionally, strategic moves like acquisitions and product launches by industry leaders are set to energize the market. For example, in October 2023, Kanvas Biosciences, a U.S.-based microbiome mapping tech firm, acquired two active therapeutic programs, a microbial library, and intellectual property from Federation Bio, known for its live biotherapeutics products. With this acquisition, Kanvas is set to push forward its Immuno-oncology and Inflammatory Bowel Disease programs. Such strategic activities not only enhance the reach of microbiome therapeutics but also bolster the market's growth.
In summary, the North American microbiome therapeutics market is poised for growth, driven by the rising prevalence of chronic diseases, technological advancements, and strategic industry activities.
Get Analysis on Important Geographic Markets
Download PDF
Microbiome Therapeutics Industry Overview
The microbiome therapeutics market is fragmented due to the presence of many startups in the field. The major players in the market are adopting various strategic activities such as mergers, collaborations, and expansions to strengthen their geographical presence and expand their customer base across the globe. Investments in the startups that are developing microbiome therapeutics are increasing to advance the microbiome therapeutic pipeline. Some of the key players in the market are OpenBiome, Seres Therapeutics, Locus Biosciences, Inc., Finch Therapeutics Group, Inc., and Intralytix, Inc., among other players.
Microbiome Therapeutics Market Leaders
-
OpenBiome
-
Seres Therapeutics
-
Locus Biosciences, Inc.
-
Finch Therapeutics Group, Inc
-
Intralytix, Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Microbiome Therapeutics Market News
- September 2024: EnteroBiotix, a Scottish biopharmaceutical company, received USD 21.5 million in investments from SIS Ventures and Kineticos Ventures in a series A round. The planned to use this funding advance its pipeline for multiple disease areas to enhance the gut microbiome.
- July 2024: Kanvas Biosciences secured an additional USD 12.5 million to enhance its innovative, microbiome-driven immuno-oncology drug candidates toward Investigational New Drug (IND) Application Filing. The company will initially harness its proprietary mapping technology to tap into the microbiome, a vital component of human health. This endeavor aims to produce a promising therapeutic, specifically targeting improvements in outcomes for cancers resistant to immune checkpoint inhibitors (ICIs).
Microbiome Therapeutics Industry Segmentation
As per the scope of the report, microbiome therapeutics are utilized in engineering the gut microbiome using additive, subtractive, or modulatory therapy with an application of native or engineered microbes, bacteriophages, and bacteriocins. The microbiome therapeutics market is segmented into therapy type, application, and geography. By therapy type, the market is segmented into fecal microbiota transplantation (FMT) and microbiome drugs. By application, the market is segmented into clostridium difficile(C.diff) Infection, Crohn’s disease, inflammatory bowel disease, diabetes, and others (obesity and oncology). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (in USD) for the above segments.
| By Therapy Type | Fecal Microbiota Transplantation (FMT) | ||
| Microbiome Drugs | |||
| By Application | Clostridium Difficile(C.diff) Infection | ||
| Crohn’s Disease | |||
| Inflammatory Bowel Disease | |||
| Diabetes | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Microbiome Therapeutics Market Research FAQs
How big is the Microbiome Therapeutics Market?
The Microbiome Therapeutics Market size is expected to reach USD 0.25 billion in 2025 and grow at a CAGR of 33.60% to reach USD 1.05 billion by 2030.
What is the current Microbiome Therapeutics Market size?
In 2025, the Microbiome Therapeutics Market size is expected to reach USD 0.25 billion.
Who are the key players in Microbiome Therapeutics Market?
OpenBiome, Seres Therapeutics, Locus Biosciences, Inc., Finch Therapeutics Group, Inc and Intralytix, Inc. are the major companies operating in the Microbiome Therapeutics Market.
Which is the fastest growing region in Microbiome Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Microbiome Therapeutics Market?
In 2025, the North America accounts for the largest market share in Microbiome Therapeutics Market.
What years does this Microbiome Therapeutics Market cover, and what was the market size in 2024?
In 2024, the Microbiome Therapeutics Market size was estimated at USD 0.17 billion. The report covers the Microbiome Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Microbiome Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Microbiome Therapeutics Industry Report
Statistics for the 2025 Microbiome Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Microbiome Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
